Münevver Demir - Concepedia

Author

Münevver Demir

Charité - Universitätsmedizin Berlin ORCID

Also Known As

Demir, M., Katharina Willuweit, Leman Bilgic, M Demir, M. Demir, Miriam Banas, Muenevver Demir, Münevver Demir, Victor de Ledinghen

204

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

Charité - Universitätsmedizin Berlin University Hospital Cologne University of Cologne Heinrich Heine University Düsseldorf Düsseldorf University Hospital

About

Münevver Demir is an author at Charité - Universitätsmedizin Berlin specializing in medicine, hepatology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	671
2	Health Sciences	6	6	612
3	Cell Biology	2	2	26
4	Public Health	1	1	35
5	Endocrinology	1	1	24

Münevver Demir

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Complement activation induces excessive T cell cytotoxicity in severe COVID-19 Philipp Georg, Rosario Astaburuaga-García, Lorenzo Bonaguro, Cell	2021	216
Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease Sonja Lang, Münevver Demir, Anna Martin, Gastroenterology HepatologyNonalcoholic Fatty Liver DiseaseLiver PhysiologyPathogenesisGastroenterology	2020	193
Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study Marcin Krawczyk, Monika Rau, Jörn M. Schattenberg, Journal of Lipid Research	2016	189
The fecal mycobiome in non-alcoholic fatty liver disease Münevver Demir, Sonja Lang, Phillipp Hartmann, Journal of Hepatology Metabolic Associated SteatohepatitisDysbiosisHepatologyNonalcoholic Fatty Liver DiseaseFecal Mycobiome	2021	168
Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis Pavel Strnad, Stephan Buch, Karim Hamesch, Gut	2018	128
[S2k Guideline non-alcoholic fatty liver disease]. Elke Roeb, Steffen Hm, Heike Bantel, PubMed ObesityMetabolic Associated SteatohepatitisHepatologyMetabolic Associated Steatotic Liver DiseaseNonalcoholic Fatty Liver Disease	2015	111
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial Stefan Traussnigg, Jörn M. Schattenberg, Münevver Demir, The Lancet. Gastroenterology & hepatology ObesityMetabolic SyndromeHepatologyMetabolic Associated Steatotic Liver DiseaseNonalcoholic Fatty Liver Disease	2019	81
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis Jana Knorr, Benedikt Kaufmann, María Eugenia Inzaugarat, Hepatology	2022	74
Treating hepatitis D with bulevirtide – Real-world experience from 114 patients Christopher Dietz-Fricke, Frank Tacke, Caroline Zöllner, JHEP Reports	2023	57
Glutathione peroxidase 4 is reversibly induced by HCV to control lipid peroxidation and to increase virion infectivity C. Brault, Pierre Lévy, Sarah Duponchel, Gut	2014	55

Page 1